Humalog, Insulin Lispro

Humalog, Insulin Lispro Newswire

Comprehensive Real-Time News Feed for Humalog, Insulin Lispro (generic).

Results 1 - 20 of 38 in Humalog, Insulin Lispro (generic)

  1. MannKind Looks Good For Long Term InvestorsRead the original story

    Wednesday Apr 29 | GuruFocus.com

    Having borne the brunt of downgrades from Wall Street analysts, such as Jay Olson of Goldman Sachs in early March, shares of MannKind Corporation have been struggling to stay above the $5 mark, and last week, they breached that level too. Even those analysts who are still bullish on the company, such as Adnan Butt of RBC Capital Markets, have cut their price targets, based on the perceived slow take-off of MannKind's inhaled diabetes drug, Afrezza.

    Comment?

  2. MKSAP: 38-year-old pregnant woman with hypertension and diabetesRead the original story w/Photo

    Sunday Apr 26 | Kevin, M.D.

    A 38-year-old woman is evaluated during a follow-up visit. She has a history of well-controlled hypertension and type 1 diabetes mellitus.

    Comment?

  3. Fitch Affirms Eli Lilly's IDR at 'A'; Outlook StableRead the original story

    Tuesday Apr 21 | Information Technology

    Fitch Ratings affirms Eli Lilly & Co. Inc.'s long-term Issuer Default Rating at 'A'.

    Comment?

  4. Humalog Canadian Pharmacy Features Humalog Insulin 100IU/mL with Lower Canada PricesRead the original story w/Photo

    Wednesday Apr 8 | OnlinePRNews

    Online PR News 08-April-2015 Montreal, QC NationDrugs.com announces its feature product Humalog Insulin 100IU/mL is now available from Canada. Humalog is a fast-acting form of insulin that works by lowering levels of glucose in the blood.

    Comment?

  5. NationDrugs.com Features Humalog Insulin 100IU/mL with Lower Canadian PricesRead the original story w/Photo

    Tuesday Apr 7 | 24-7 Press Release

    MONTREAL, QC, April 08, 2015 /24-7PressRelease/ -- NationDrugs.com announces its feature product Humalog Insulin 100IU/mL is now available from Canada. Humalog is a fast-acting form of insulin that works by lowering levels of glucose in the blood.

    Comment?

  6. FDA: Stop Sharing Insulin PensRead the original story w/Photo

    Mar 2, 2015 | Medical Device/Diagnostic Ind.

    In recent years, there have been large-scale incidents of patients sharing insulin pens, and FDA wants to put a stop to it. issued last week, FDA said it is requiring makers of pens for injecting insulin and other diabetes medications to add wording to label warning against sharing the devices.

    Comment?

  7. Lilly diabetes drug trial haltedRead the original story

    Feb 23, 2015 | Business World

    Eli Lilly said it would postpone by at least two years the marketing application for its once-daily diabetes treatment to evaluate liver concerns, a delay some analysts said could doom the experimental drug. Lilly said it wouldn't seek U.S. and European marketing approval for basal insulin peglispro until "after 2016," as it attempts to find out why some patients developed excess liver fat in late-stage studies..

    Comment?

  8. UPDATE 1-Lilly long-acting insulin delayed by liver concernsRead the original story

    Feb 23, 2015 | Reuters

    Eli Lilly and Co said it would postpone by at least two years the marketing application for its once-daily diabetes treatment to evaluate liver concerns, a delay some analysts said could doom the experimental drug. Lilly said it wouldn't seek U.S. and European marketing approval for basal insulin peglispro until "after 2016," as it attempts to find out why some patients developed excess liver fat in late-stage studies..

    Comment?

  9. China Fastest Growing Human Insulin Market Globally for Next 5 YearsRead the original story

    Feb 20, 2015 | Sys-Con Media

    Global and Chinese Human Insulin Industry, 2009-2019 Market Research Report and Human Insulin Market by Product Type , Modern Human Insulin , by Brand - Forecast to 2018 are research reports now available with LifeScienceIndustryResearch.com. will also emerge as lucrative markets for human insulin market.

    Comment?

  10. Biodel's (BIOD) CEO Errol De Souza on Q1 2015 Results - Earnings Call TranscriptRead the original story w/Photo

    Feb 12, 2015 | Seeking Alpha

    Ladies and gentlemen, thank you for standing by. Welcome to Biodel's First Quarter Fiscal Year 2015 Financial Results Conference Call.

    Comment?

  11. Biodel Reports First Quarter Fiscal Year 2015 Financial ResultsRead the original story

    Feb 12, 2015 | Freshnews

    Reported Phase 2a meal study data for Study 3-151, which demonstrated superior post-meal glucose control of BIOD-531 compared to marketed prandial/basal insulins Humalog On track for completion of dosing in the middle of February 2015 of Study 6-101 Phase 1 proof of concept study in the Glucagon Emergency Management Program to compare the pharmacokinetic and pharmacodynamic properties of BIOD-961 to two marketed glucagon products; announcement of top line data projected towards the end of first calendar quarter 2015 On track for initiation in the second calendar quarter of 2015 of multi-dose Phase 2b Study 3-250 in type 2 diabetes patients with moderate insulin resistance who will receive BIOD-531 or Humalog Dr. Errol De Souza, president and chief executive officer of Biodel, stated: "We are off to a great start in 2015.

    Comment?

  12. Fast-Acting Human Insulin, HinsBet, Shows Promise in Mid-Stage TrialRead the original story

    Feb 6, 2015 | P&T Community

    Positive results have been reported from a phase IIa clinical trial evaluating a fast-acting formulation of recombinant human insulin, HinsBet , in comparison with Humalog and Humulin , both marketed by Eli Lilly. The new study met its primary endpoint: the increase in recombinant human insulin bioavailability during the first hour of therapy with HinsBet compared with Humulin.

    Comment?

  13. Adocia Reports Positive Results From Phase 2a Clinical Study Of Fast-Acting Insulin, HinsBetRead the original story

    Feb 4, 2015 | BioSpace

    HinsBet is significantly faster than human insulin in type 1 diabetic patients; onset of action is 70 percent earlier and early metabolic effect is doubled; HinsBet's fast action is similar to that of Humalog in the first hour which is critical for glycemic control; A concentrated formulation of HinsBet at 500 IU/ml is under development to answer the needs of the growing population of severely resistant diabetic patients. Lyon, France, February 05, 2015 - Adocia today announced positive results from a Phase IIa clinical trial evaluating its innovative fast-acting formulation of recombinant human insulin, HinsBet, in comparison to Eli Lilly's commercial products, Humalog and Humulin .

    Comment?

  14. IPO Preview: Asante SolutionsRead the original story w/Photo

    Feb 4, 2015 | Seeking Alpha

    Based in Sunnyvale, CA, Asante Solutions scheduled a $49 million IPO on Nasdaq with a market capitalization of $167 million at a price range midpoint of $14 for Thursday, Feb. 5, 2015. Summary PUMP is a medical device company with the mission of improving and simplifying the management of diabetes patients and healthcare practitioners.

    Comment?

  15. Adocia initiates a clinical study on the post-meal effect of...Read the original story w/Photo

    Jan 22, 2015 | Medical News Today

    Adocia has announced the initiation of a Phase Ib clinical trial evaluation for BioChaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Eli Lilly and Company. This formulation uses Adocia's proprietary technology BioChaperone, which is believed to enable the acceleration of insulin absorption.

    Comment?

  16. Adocia Initiates A Clinical Study On The Post-Meal Effect Of...Read the original story

    Jan 20, 2015 | BioSpace

    This single-dose Phase Ib clinical trial in patients with type 1 diabetes is designed to evaluate any change in post-meal glycemic control after injection of BioChaperone Lispro, as compared to Humalog, at the time of the meal. This trial, led by Adocia, is the first study in the clinical development plan established as part of the Adocia-Lilly partnership.

    Comment?

  17. Ask D'Mine: The 'Right' Path to Control, (Thankfully) Nothing Lasts ForeverRead the original story w/Photo

    Jan 10, 2015 | Diabetes Mine

    Welcome back to our weekly diabetes advice column, Ask D'Mine - with your host veteran type 1, diabetes author and educator W il Dubois . This week, Wil takes on a couple of question about low-carb, high-fat diets and some not-so-pleasant complications that just add more to the mixed health bag people with diabetes are already carrying.

    Comment?

  18. Does Sanofi's $50 Million Milestone Payment to MannKind Corp. Matter?Read the original story w/Photo

    Jan 8, 2015 | The Motley Fool

    Delivering the goods MannKind and Sanofi are poised this quarter to finally launch Afrezza, a highly anticipated, fast-acting oral insulin that is inhaled rather than delivered via injection. last year, and its fits and starts over the past half decade caused a string of stock price pops and drops.

    Comment?

  19. Eli Lilly Lowers Earnings Estimate And Refines Strategy, But Long-Term Story IntactRead the original story w/Photo

    Jan 7, 2015 | Seeking Alpha

    Eli Lilly expects to grow its revenue with a first group of products in diabetes, oncology and immunology, followed by a second group of potential products. The company indicated that it will focus its internal research and development on the core areas of diabetes, oncology, neurodegeneration, immunology and pain.

    Comment?

  20. Biodel's Concentrated Insulin BIOD-531 Demonstrates Superior...Read the original story w/Photo

    Jan 7, 2015 | Market Wire

    In the primary efficacy analysis, BIOD-531 was associated with superior glucose control compared to HumulinA R U-500 and HumalogA Mix 75/25 when the insulins were dosed immediately before breakfast. Over a 24 hour period of observation, BIOD-531 and HumulinA R U-500 were associated with superior glucose control compared to HumalogA Mix 75/25 when dosed immediately before the breakfast and dinner meals.

    Comment?